| abstract |
The present invention relates to the novel use of the active ingredient Pidotimod or a stereoisomer thereof and/or a physiologically acceptable salt thereof for the treatment of an inflammation-related disease characterized by abnormal abnormality of the atypical NFkB pathway. Hyperactivation, such as allergic diseases, autoimmune diseases, or other inflammatory diseases based on mechanisms other than allergic or autoimmune mechanisms. |